Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.
COVID-19
DMD
MS therapy-related risks
S1P-modulators
SARS-CoV-2
anti-CD20
fingolimod
multiple sclerosis
ocrelizumab
vaccination
Journal
Neurology international
ISSN: 2035-8385
Titre abrégé: Neurol Int
Pays: Switzerland
ID NLM: 101551564
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
received:
24
02
2022
revised:
05
04
2022
accepted:
13
04
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination response in pwMS, there is a scarcity of reviews integrating both these aspects into strategies aimed at minimizing risks. The aim of this review is to describe the risk of vulnerable pwMS exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the issues related to the SARS-CoV-2 vaccine and to evidence possible future strategies in the clinical management of pwMS. The authors searched for papers on severe COVID-19 risk factors, SARS-CoV-2 vaccination and people with multiple sclerosis in support of this narrative literature review. We propose a multilevel strategy aimed at: the evaluation of risk factors for severe COVID-19 in people with multiple sclerosis, identifying the most appropriate vaccination schedule that is safe for people on disease-modifying drugs (DMDs) and a strict follow-up of high-risk people with multiple sclerosis to allow for the prompt administration of monoclonal antibodies to manage COVID-19 risks in this patient population.
Identifiants
pubmed: 35466211
pii: neurolint14020030
doi: 10.3390/neurolint14020030
pmc: PMC9036272
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
368-377Références
Ther Adv Neurol Disord. 2021 May 29;14:17562864211020082
pubmed: 34104221
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler Relat Disord. 2022 Jan;57:103358
pubmed: 35158467
Crit Care. 2020 May 15;24(1):228
pubmed: 32414403
Transl Psychiatry. 2021 Jan 21;11(1):67
pubmed: 33479211
Neurol Clin. 2011 May;29(2):207-17
pubmed: 21439437
EBioMedicine. 2022 Jun;80:104042
pubmed: 35526306
Int J Stroke. 2020 Aug;15(6):701-702
pubmed: 32568626
Mult Scler. 2022 Mar 16;:13524585221079598
pubmed: 35296189
Diagnostics (Basel). 2022 Jan 06;12(1):
pubmed: 35054296
Biomedicines. 2021 May 06;9(5):
pubmed: 34066395
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Am J Med. 2020 Dec;133(12):1380-1390.e2
pubmed: 32682869
Neurology. 2022 Feb 1;98(5):e541-e554
pubmed: 34810244
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):
pubmed: 34753829
Exp Brain Res. 2020 Sep;238(9):2009-2018
pubmed: 32617883
Neurol Int. 2021 Dec 06;13(4):695-700
pubmed: 34940752
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744
pubmed: 34240579
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Crit Care. 2020 Oct 29;24(1):627
pubmed: 33121512
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
Lancet Neurol. 2021 Aug;20(8):653-670
pubmed: 34139157
J Neurol. 2022 Mar;269(3):1114-1120
pubmed: 34533590
Front Neurol. 2021 Oct 22;12:765954
pubmed: 34744992
Health Info Libr J. 2009 Jun;26(2):91-108
pubmed: 19490148
Eur J Neurol. 2022 May;29(5):1538-1544
pubmed: 35102646
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2):
pubmed: 35105687
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Mult Scler. 2022 Jan;28(1):132-138
pubmed: 33764197
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):448-450
pubmed: 34408003
Biomedicines. 2020 Oct 12;8(10):
pubmed: 33053739
Ann Neurol. 2014 Dec;76(6):802-12
pubmed: 25273271
Neuroscientist. 2020 Oct-Dec;26(5-6):402-414
pubmed: 32684080
Sci Rep. 2021 Jan 28;11(1):2611
pubmed: 33510396
Int J Mol Sci. 2020 Dec 08;21(24):
pubmed: 33302404
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Eur Neurol. 2020;83(2):220-221
pubmed: 32392566
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Mult Scler. 2020 Apr;26(5):540-547
pubmed: 31965903
Mult Scler. 2022 Jun;28(7):1155-1159
pubmed: 34931885
Brain. 2019 Jul 1;142(7):1858-1875
pubmed: 31209474
Med Intensiva. 2021 Aug-Sep;45(6):383-384
pubmed: 34629590